ABSTRACT
Cardiac arrest (CA) is one of the leading causes of death worldwide. Due to hypoxic ischemic brain injury, CA survivors may experience variable degrees of neurological dysfunction. This study, for the first time, describes the progression of CA-induced neuropathology in the rat. CA rats displayed neurological and exploratory deficits. Brain MRI revealed cortical and striatal edema at 3 days (d), white matter (WM) damage in corpus callosum (CC), external capsule (EC), internal capsule (IC) at d7 and d14. At d3 a brain edema significantly correlated with neurological score. Parallel neuropathological studies showed neurodegeneration, reduced neuronal density in CA1 and hilus of hippocampus at d7 and d14, with cells dying at d3 in hilus. Microgliosis increased in cortex (Cx), caudate putamen (Cpu), CA1, CC, and EC up to d14. Astrogliosis increased earlier (d3 to d7) in Cx, Cpu, CC and EC compared to CA1 (d7 to d14). Plasma levels of neurofilament light (NfL) increased at d3 and remained elevated up to d14. NfL levels at d7 correlated with WM damage. The study shows the consequences up to 14d after CA in rats, introducing clinically relevant parameters such as advanced neuroimaging and blood biomarker useful to test therapeutic interventions in this model.
ABSTRACT
Previous studies have shown that adolescent exposure to cocaine increases drug use in adulthood, albeit incubation of cocaine seeking was found to be attenuated in rats trained to self-administer cocaine during adolescence. We here hypothesize that adolescent exposure to cocaine could alter the rewarding properties of the psychostimulant in adulthood. By employing two of the most widely used animal-experimental-preclinical models to investigate drug addiction, we evaluated whether contingent versus non-contingent cocaine self-administration during adolescence modulates its rewarding threshold in adulthood evaluated by conditioned place preference (CPP). Cocaine self-administration during adolescence increases the rewarding threshold in adulthood; CPP for cocaine was observed at the higher (20 mg/kg), but not at the lower (10 mg/kg), dose employed. Rats exposed to either contingent or non-contingent cocaine during adolescence exhibited the same behavior in the CPP paradigm suggesting that, under our experimental conditions, cocaine rewarding properties are shaped by the psychostimulant itself and not by its motivational effects. From a mechanistic standpoint, the preference for the 20 mg/kg cocaine-paired side in a CPP paradigm appears to depend, at least partially, upon the formation of GluA2-lacking Ca2+ -permeable AMPA receptors and the consequent increase of αCaMKII activity in the NAc, both of which are instead reduced when the 10 mg/kg dose was used. In conclusion, contingent or non-contingent cocaine exposure during adolescence desensitizes adult animals to a rewarding dose of cocaine (10 mg/kg) elevating the rewarding threshold necessary (20 mg/kg) to drive conditioned place preference, an effect that may predispose to higher consumption of cocaine during adulthood.
Subject(s)
Cocaine/pharmacology , Conditioning, Classical/drug effects , Animals , Central Nervous System Stimulants/pharmacology , Female , Male , Motivation , Rats , Receptors, AMPA , Reward , Self AdministrationABSTRACT
Nicotine-associated cues can trigger reinstatement in humans as well as in animal models of drug addiction. To date, no behavioral intervention or pharmacological treatment has been effective in preventing relapse in the long term. A large body of evidence indicates that N-acetylcysteine (N-AC) blunts the activation of glutamatergic (GLUergic) neurons in the nucleus accumbens (Nacc) associated with reinstatement. We evaluated the effect of an experimental cue exposure therapy (eCET) alone or in combination with N-AC to verify whether restoring GLU homeostasis enhances extinction of nicotine-associated cues. Rats were trained to associate discriminative stimuli with intravenous nicotine or saline self-administration. Reinforced response was followed by cue signals. After rats met the self-administration criteria, the lasting anti-relapse activity of i.p. N-AC or vehicle was assessed in three different experimental conditions after 14 days of treatment: treatment + eCET; treatment + lever-presses extinction (LP-EXT); and treatment + abstinence. N-AC 100 mg/kg, but not 60 mg/kg, induced anti-relapse activity that persisted 50 days after treatment only when paired with either LP-EXT or eCET with the greater activity found in the latter condition. To identify potential mechanisms for behavioral results, separate groups of rats that received either N-AC or vehicle + eCET were killed at different time points for Nacc Western-blot analysis. Seven days after treatment, chronic N-AC restored the expression of proteins crucial for GLU homeostasis, while at 50 days, it increased the expression of type II metabotropic GLU receptors. These results suggest that N-AC treatment in combination with eCET may offer a novel strategy to prevent relapse in nicotine addiction.
Subject(s)
Acetylcysteine/pharmacology , Cues , Drug-Seeking Behavior/drug effects , Free Radical Scavengers/pharmacology , Glutamic Acid/metabolism , Nicotine/administration & dosage , Nicotinic Agonists/administration & dosage , Tobacco Use Disorder , Animals , Behavior, Animal , Extinction, Psychological , Implosive Therapy , Male , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Rats , Receptors, AMPA/drug effects , Receptors, AMPA/metabolism , RecurrenceABSTRACT
Electromagnetic field (EMF) technology has the potential to improve scientific data capture and welfare assessment by allowing automated data collection from individual cages. However, it is important to determine any impact that a new technology itself may have on animal welfare, and previous studies have found contrasting results of EMF on laboratory rodent anxiety-like behaviour and cognition. We therefore investigated whether there was an effect of low frequency EMF experienced continuously over a six-week period, as an integral part of the animal housing system, on measures of mouse anxiety-related behaviour, cognition and welfare. We housed mice (N = 80) of two strains (BALB/cAnNCrl and C57BL/6NCrl) separately in Individually Ventilated Cages (IVCs) in groups of four, either with the EMF plate turned 'on' or 'off' (n = 5). Some measures, e.g. food and water utilisation, were collected at regular intervals, whereas measures of anxiety-like behaviour (e.g. open field test) and cognitive performance (novel-object recognition test) were collected only at the end of the study. We found expected strong strain differences in most measures, e.g. latency to leave the starting square in an open field test, with C57BL/6NCrl mice moving away sooner, and interactions between strain and time for those measures recorded at more than one time point, e.g. significant weight gain over time for both strains, but with BALB/cAnNCrl mice weighing more. However, we found no significant effects of treatment (EMF 'on'/'off') for any of the measures collected. These results indicate that, for the measures recorded here, there was no measurable impact on the behaviour and welfare of low frequency EMF exposure experienced continuously over a six-week period. Housing systems that include EMF monitoring technology may therefore be suitable for use without influencing either animal welfare or scientific outcomes.
Subject(s)
Anxiety/physiopathology , Behavior, Animal , Cognition , Electromagnetic Fields , Animals , Female , Mice , Mice, Inbred BALB C , Species SpecificityABSTRACT
3,4-Dichloro-N-benzamide (AH-7921) is a cyclohexyl-methylbenzamide derivative with analgesic activity, whose abuse was associated with several fatal intoxications, included in Schedule I of UN Single Convention on Narcotic Drugs. We validated an HPLC-MS/MS method to investigate its brain disposition and metabolism after single and repeated injections; in parallel, we evaluated its central behavioral effects. After an intraperitoneal injection of 10â¯mg/kg, the analgesic effect appeared after 5â¯min and persisted up to 4â¯h; brain absorption was rapid (tmax 30â¯min) and large (brain-to-plasma ratio 16), with active concentration >700â¯ng/g. By high-resolution MS we identified several metabolites in plasma and brain, the most important being N-demethylated and N,N-didemethylated metabolites; they showed high brain permeability, although they probably do not contribute to the analgesic effect of the parent compound (brain tmax>2â¯h). Starting 2â¯h after treatment, the two metabolites showed higher plasma and brain concentrations than the parent molecule, which persisted much longer, and could be used to evaluate drug intake in human consumers. Tolerance was observed after seven daily doses, when the compound's analgesic effect was 14% lower than after the first dose; since brain concentrations did not decrease in parallel, the development of pharmacodynamic tolerance can be suggested. However, pharmacokinetic tolerance is also likely, as brought to light by the data after a dose challenge, given after a 48â¯h washout period from the 7th dose, showing a lower brain-to-plasma ratio. We also describe the rewarding effect of AH-7921 (conditioned place preference), suggesting a high risk of addiction in humans.
Subject(s)
Analgesics, Opioid/pharmacology , Behavior, Animal/drug effects , Benzamides/pharmacology , Brain/drug effects , Brain/metabolism , Analgesics, Opioid/chemical synthesis , Animals , Benzamides/blood , Benzamides/chemistry , Chromatography, High Pressure Liquid , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Male , Metabolic Networks and Pathways/drug effects , Rats , Rats, Wistar , Tandem Mass Spectrometry , Time FactorsABSTRACT
Chronic self-administration of nicotine induces maladaptive changes in the cortico-accumbal glutamate (Glu) network. Consequently, re-exposure to nicotine-associated cues raises extracellular Glu in the nucleus accumbens reinstating drug-seeking. Restoring basal concentrations of extracellular Glu, thereby increasing tonic activation of the presynaptic group II metabotropic Glu receptors (mGluR2/3) with N-acetylcysteine (N-AC), might offer a valid therapeutic approach for maintaining smoking abstinence. Although N-AC modulates nicotine-seeking behavior by drug-associated stimuli in abstinent rats, it is still unclear whether it occurs through activation of mGluR2/3. Male Wistar rats were trained to associate discriminative stimuli (SD s) with the availability of intravenous nicotine (0.03 mg/kg/65 µl/2-second/infusion) or oral saccharin (100 µl of 50 mg/l) self-administration versus non-reward. Reinforced response was followed by a cue signaling 20-second time-out (CSs). Once the training criterion was met, rats underwent lever press extinction, without reinforcers, SD s and CSs. Re-exposure to nicotine or saccharin SD+ /CS+ , but not non-reward SD- /CS- , revived responding on the previously reinforced lever. Acute N-AC, 100 but not 60 or 30 mg/kg i.p., reduced cue-induced nicotine-seeking. N-AC 100 mg/kg did not modify cue-induced saccharin-seeking behavior or influenced locomotor activity. Blocking mGluR2/3 with the selective antagonist LY341495, 1 mg/kg i.p., completely prevented the antirelapse activity of N-AC. The finding that N-AC prevents cue-induced nicotine-seeking by stimulating mGluR2/3 might indicate a therapeutic opportunity for acute cue-controlled nicotine-seeking. Future studies could evaluate the persistent effects of chronic N-AC in promoting enduring suppression of nicotine-cue conditioned responding.
Subject(s)
Acetylcysteine/pharmacology , Drug-Seeking Behavior/drug effects , Glutamic Acid/drug effects , Nicotine/administration & dosage , Nicotinic Agonists/administration & dosage , Receptors, Metabotropic Glutamate/metabolism , Amino Acids/pharmacology , Animals , Conditioning, Operant , Cues , Excitatory Amino Acid Antagonists/pharmacology , Glutamic Acid/metabolism , Locomotion/drug effects , Male , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Rats , Rats, Wistar , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Self Administration , Xanthenes/pharmacologyABSTRACT
para-Methyl-4-methylaminorex (4,4'-DMAR) is a phenethylamine derivative with psychostimulant activity whose abuse has been associated with several deaths and a wide range of adverse effects. We recently validated a high-performance liquid chromatography-tandem mass spectrometry method to measure the compound's concentrations in plasma, and we applied it to describe the pharmacokinetic properties of 4,4'-DMAR after a single dose in rats. In this study, we investigated the brain disposition and metabolism of cis-4,4'-DMAR after intraperitoneal injection as well as its central behavioral effects. Locomotor activity increased after a single injection of 10 mg/kg, peaking at 2 hours and disappearing at 5 hours; in these conditions, brain absorption was very rapid, (tmax = 30-60 minutes) and large (brain-to-plasma ratio = 24); the half-life was approximately 50 minutes. After 14 daily doses, the compound's effect on locomotor activity was greater (approximately 20% compared with the effect after the first dose), but not for pharmacokinetic reasons. Using high-resolution mass spectrometry, we also identified four metabolites of cis-4,4'-DMAR in the plasma and brain of treated rats. Semiquantitative analysis indicated low brain permeability and very low brain concentrations, suggesting that these metabolites do not contribute to central behavioral effects; however, the metabolite originating from oxidation of the para-methyl group (M2) persisted in the plasma longer and at higher concentrations than the parent molecule and could be used to evaluate drug intake in human consumers. Finally, we describe the rewarding effect of cis-4,4'-DMAR in the conditioning place preference test, suggesting a high risk of addiction in humans.
Subject(s)
Brain/metabolism , Illicit Drugs/metabolism , Illicit Drugs/pharmacology , Locomotion/drug effects , Oxazoles/administration & dosage , Oxazoles/metabolism , Animals , Brain/drug effects , Drug Administration Schedule , Locomotion/physiology , Male , Rats , Rats, Wistar , Tissue Distribution/drug effects , Tissue Distribution/physiologyABSTRACT
PURPOSE: Asparaginase (ASNase) is used to treat various hematological malignancies for its capacity to deplete asparagine (ASN) in serum and cerebrospinal fluid (CSF). Since the biological mechanisms underlying CSF asparagine depletion in humans are not yet fully elucidated, this study compared, for the first time, the pharmacological properties of three clinically used ASNase formulations in a rodent model. METHODS: Male Wistar rats were treated with E.coli-ASNase, PEG-ASNase, or ERW-ASNase at different doses. Serum and CSF amino-acid levels and ASNase activities were evaluated at 1 and 24 h after the intravenous administration of different ASNase doses. RESULTS: All the ASNase formulations showed higher activities in serum after 1 h than 24 h and completely deplete ASN. Mean ASNase activity in the CSF at 1 h was higher with ERW-ASNase compared to PEG-ASNase (36 ± 29 vs 8 ± 7 U/L, p < 0.037) and similar to E.coli-ASNase (21 ± 9 U/L, ns). ERW-ASNase and E.coli-ASNase at the highest doses were able to deplete ASN in the CSF after 1 h. This effect was transient and not evident at 24 h after treatment. CONCLUSIONS: Together with the ASN depletion in serum and CSF, a never before demonstrated transient penetration of ASNases into the CSF, more evident for non-pegylated formulations, was detected when the ASNases were administered at high dose.
Subject(s)
Antineoplastic Agents/cerebrospinal fluid , Antineoplastic Agents/pharmacokinetics , Asparaginase/cerebrospinal fluid , Asparaginase/pharmacokinetics , Administration, Intravenous , Animals , Antineoplastic Agents/administration & dosage , Asparaginase/administration & dosage , Blood-Brain Barrier/metabolism , Dickeya chrysanthemi/enzymology , Drug Compounding , Escherichia coli/enzymology , Half-Life , Male , Molecular Weight , Polyethylene Glycols/chemistry , Rats , Rats, WistarABSTRACT
4,4'-DMAR is an analogue of the known psychostimulants 4-methylaminorex and aminorex. In the light of reports of deaths associated with its abuse, and the easy access from Internet vendors, the EU Council recently decided on control measures across member states. Here we describe a validated method for measuring plasma levels of cis-4,4'-DMAR, crucial for preclinical studies and analysis in human plasma. Chromatographic separation was done by gradient elution on a Kinetex C18 column with 0.1% formic acid in water and 0.1% formic acid in acetonitrile at 0.2 mL/min. Detection was by positive electrospray ionization (ESI+) in multiple reaction monitoring mode monitoring the quantifier transitions m/z 191.4 â m/z 148.3 for cis-4,4'-DMAR and m/z 259.3 â m/z 194.2 for carbamazepine (internal standard). Protein precipitation with 1% of formic acid in acetonitrile was used in cis-4,4'-DMAR extraction from plasma; recovery was high (>93%) with a negligible matrix effect. This method provides an accurate, precise, and sensitive method for cis-4,4'-DMAR quantification in human and rat plasma, following European Medicine Agency guidelines for bioanalytical method validation. Pharmacokinetic studies were conducted in rats. After an intravenous dose of 1 mg/kg, plasma levels declined rapidly (≥80% in 4 h), followed by a slow elimination phase (t1/2 of 5.14 ± 0.65 h). Absorption was rapid after intraperitoneal injection (tmax = 15 min) with a rapid decline thereafter; Cmax and AUC0-240min showed dose-proportionality over the dose range 1-10 mg/kg. This method was successfully applied to investigate pharmacokinetic properties in rats and could be used to quantify cis-4,4'-DMAR levels in human plasma. Copyright © 2016 John Wiley & Sons, Ltd.
Subject(s)
Chromatography, High Pressure Liquid/methods , Illicit Drugs/blood , Oxazoles/blood , Psychotropic Drugs/blood , Tandem Mass Spectrometry/methods , Animals , Humans , Limit of Detection , Male , Rats , Rats, Wistar , Substance Abuse Detection/methodsABSTRACT
RATIONALE: Although brain-derived neurotrophic factor (BDNF) is part of a homeostatic pathway involved in the development of alcohol dependence, it is not clear whether this is also true after recreational ethanol consumption. OBJECTIVES: We examined BDNF expression and signaling in the cortico-striatal network immediately and 24 h after either a single intravenous (i.v.) ethanol operant self-administration session or the last of 14 sessions. METHODS: To compare contingent and non-contingent ethanol exposure, we incorporated the "yoked control-operant paradigm" in which rats actively taking ethanol (S-Et) were paired with two yoked controls receiving passive infusions of ethanol (Y-Et) or saline. RESULTS: A single ethanol exposure transiently reduced BDNF mRNA levels in the medial prefrontal cortex (mPFC) of Y-Et. Immediately after the last of 14 sessions, mRNA and mature BDNF protein levels (mBDNF) were reduced in the mPFC in both S-Et and Y-Et while mBDNF expression was raised in the nucleus accumbens (NAc), suggesting enhanced anterograde transport from the mPFC. Conversely, 24 h later mBDNF expression and signaling were raised in the mPFC and NAc of S-Et rats but reduced in the NAc of Y-Et rats, with concomitant reduction of downstream signaling pathways. CONCLUSIONS: Our findings indicate that recreational-like i.v. doses of ethanol promote early changes in neurotrophin expression, depending on the length and modality of administration, the brain region investigated, and the presence of the drug. A rapid intervention targeting the BDNF system might be useful to prevent escalation to alcohol abuse.
Subject(s)
Brain-Derived Neurotrophic Factor/drug effects , Central Nervous System Depressants/pharmacology , Conditioning, Operant , Ethanol/pharmacology , Nucleus Accumbens/drug effects , Prefrontal Cortex/drug effects , RNA, Messenger/drug effects , Animals , Brain/metabolism , Brain-Derived Neurotrophic Factor/genetics , Central Nervous System Depressants/administration & dosage , Ethanol/administration & dosage , Male , Neostriatum/drug effects , Neostriatum/metabolism , Nucleus Accumbens/metabolism , Prefrontal Cortex/metabolism , RNA, Messenger/metabolism , Rats , Rats, Wistar , Self Administration , Signal Transduction/drug effectsABSTRACT
We previously demonstrated that nELAV/GAP-43 pathway is pivotal for learning and its hippocampal expression is up-regulated by acute stress following repeated cocaine administration. We therefore hypothesized that abstinence-induced stress may sustain nELAV/GAP-43 pathway during early abstinence following 2 weeks of cocaine self-administration. We found that contingent, but not non-contingent, cocaine exposure selectively increases hippocampal nELAV, but not GAP-43, expression immediately after the last self-administration session, an effect that wanes after 24 h and that comes back 7 days later when nELAV activation becomes associated with increased expression of GAP-43, an effect again observed only in animals self-administering the psychostimulant. Such effect is specific for nELAV since the ubiquitous ELAV/HuR is unchanged. This nELAV profile suggests that its initial transient alteration is perhaps related to the daily administration of cocaine, while the increase in the nELAV/GAP-43 pathway following a week of abstinence may reflect the activation of this cascade as a target of stressful conditions associated with drug-related memories. © 2016 Wiley Periodicals, Inc.
Subject(s)
Central Nervous System Stimulants/administration & dosage , Cocaine/administration & dosage , GAP-43 Protein , Hippocampus/metabolism , Substance Withdrawal Syndrome/metabolism , Animals , Blotting, Western , Cocaine-Related Disorders/metabolism , Cocaine-Related Disorders/psychology , Disease Models, Animal , ELAV-Like Protein 1/metabolism , GAP-43 Protein/metabolism , Rats , Self Administration , Signal Transduction , Stress, Psychological/etiology , Stress, Psychological/metabolismABSTRACT
Increases in alpha calcium/calmodulin-dependent protein kinase type II (αCaMKII) activity in the nucleus accumbens shell has been proposed as a core component in the motivation to self-administer cocaine and in priming-induced drug-seeking. Since cocaine withdrawal promotes drug-seeking, we hypothesized that abstinence from cocaine self-administration should enhance αCaMKII as well. We found that short-term abstinence from contingent, but not non-contingent, cocaine i.v. self-administration (2 h/d for 14 d; 0.25 mg/0.1 ml, 6 s infusion) elevates αCaMKII autophosphorylation, but not the kinase expression, in a dynamic, time- and brain region-dependent manner. Increased αCaMKII autophosphorylation in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), but not dorsolateral striatum (dlS), was found 24 h, but not immediately, after the last cocaine self-administration session. Notably, in the mPFC, but not NAc and dlS, αCaMKII autophosphorylation was still enhanced 7 d later. The persistent enhancement in the mPFC of abstinent rats may represent a previously unappreciated contribution to initial incubation of cocaine-seeking.
Subject(s)
Behavior, Addictive/enzymology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Cocaine/administration & dosage , Nucleus Accumbens/enzymology , Prefrontal Cortex/enzymology , Substance Withdrawal Syndrome/enzymology , Animals , Behavior, Addictive/psychology , Cocaine/adverse effects , Infusions, Intravenous , Male , Nucleus Accumbens/drug effects , Phosphorylation/drug effects , Phosphorylation/physiology , Prefrontal Cortex/drug effects , Rats , Rats, Sprague-Dawley , Self Administration , Substance Withdrawal Syndrome/psychology , Time FactorsABSTRACT
Pharmacological stimulation of N-methyl-D-aspartate receptors (NMDAr) could enhance the outcome of cue-exposure therapy for smoking cessation. NMDAr stimulation can be achieved by increasing pharmacologically the synaptic levels of glycine, a necessary co-agonist. Here, we evaluate the effects of SSR504734, a selective inhibitor of glycine type I transporter (GlyT1) in an extinction-reinstatement procedure inducing robust and lasting nicotine-seeking behavior in rats. Male Wistar rats were trained to associate discriminative stimuli (S(D)s) with the availability of nicotine (0.03 mg/kg/65 µL/2 second/infusion) or sucrose (45-mg pellet) versus non-reward in two-lever operant cages. Reinforced response was followed by cue signaling 20-second time-out (CSs). Once the training criterion was met, rats underwent extinction of lever presses, in the absence of reinforcers, S(D) s and CSs. Re-exposure to nicotine or sucrose S(D+)/CS(+), but not non-reward S(D-)/CS(-), revived responding at the previously reinforced lever. Acute pre-treatment with SSR504734 (10 mg/kg i.p.) reduced nicotine-seeking but not sucrose-seeking behavior without influencing rats' locomotor activity. Sub-chronic treatment (10 mg/kg i.p. for 5 days) during daily exposure to S(D+)/CS(+) reduced nicotine-seeking; however, this effect was transient, with return to S(D+)/CS(+) responding at 72 hours. Full recovery to S(D+)/CS(+) responding was observed after 1 month suggesting that SSR504734 sub-acute treatment did not engage the long-term plasticity mechanisms probably involved in nicotine-seeking. In conclusion, GlyT1-inhibitors might offer a therapeutic opportunity for acute cue-controlled nicotine-seeking, but the lack of persistent effects of the sub-chronic treatment associated with nicotine cues exposure suggests that short-term administration of GlyT1-inhibitor SSR504734 is not sufficient to promote extinction of nicotine-cue conditioned responding.
Subject(s)
Benzamides/pharmacology , Conditioning, Psychological/drug effects , Drug-Seeking Behavior/drug effects , Extinction, Psychological/drug effects , Glycine Plasma Membrane Transport Proteins/antagonists & inhibitors , Nicotine , Piperidines/pharmacology , Analysis of Variance , Animals , Benzamides/administration & dosage , Cues , Discrimination Learning/drug effects , Dose-Response Relationship, Drug , Implosive Therapy , Male , Motor Activity/drug effects , Piperidines/administration & dosage , Random Allocation , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/agonists , Self Administration , Sucrose/administration & dosageABSTRACT
Brain-derived neurotrophic factor (BDNF) dynamic changes were investigated in the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc) during use and the early phases of cocaine abstinence after 14 sessions (2 h self-administration/d; 0.25 mg/0.1 ml.6 s infusion) by employing a 'yoked control-operant paradigm'. The effect on BDNF was region-specific and dependent on the withdrawal time. In the NAc, BDNF protein levels increased immediately after the last self-administration session, with a larger increase in passively cocaine-exposed rats. In the mPFC, BDNF expression was elevated 24 h after the last self-administration session, independently of how the drug was encountered. No changes were found in NAc and mPFC 7 d after the last self-administration session. Analysis of transcript levels in the mPFC indicated that action on exon I might contribute to BDNF's cortical induction. These findings indicate a finely tuned modulation of BDNF expression during use and early phases of cocaine abstinence.
Subject(s)
Brain-Derived Neurotrophic Factor/biosynthesis , Cocaine/administration & dosage , Gene Expression Regulation , Nucleus Accumbens/metabolism , Prefrontal Cortex/metabolism , Animals , Infusions, Intravenous , Male , Nucleus Accumbens/drug effects , Prefrontal Cortex/drug effects , Rats , Rats, Sprague-Dawley , Self AdministrationABSTRACT
RATIONALE: With its high palatability, near-beer has been successfully used in rats as a vehicle to induce ethanol oral self-administration. OBJECTIVES: The study aimed to develop an operant model of oral alcoholic beer self-administration promoting a stable intake of pharmacologically relevant amounts of ethanol in free-feeding C57BL/6J mice. It also aimed to assess the model's predictive validity by evaluating the influence of baclofen, a GABA(B) agonist, and BHF177, a GABA(B) positive allosteric modulator, on alcoholic beer self-administration. METHODS: Mice were trained to self-administer, under a fixed ratio three schedule of reinforcement, 10 µl of beer containing increasing ethanol concentrations (0-18% v/v) in daily 30-min sessions. The effects on motor coordination (rotarod), locomotor activity (open field, automated cages) and anxiety-like behavior (elevated plus maze, EPM) were examined. Baclofen (1.25-5 mg/kg, intraperitoneal, i.p.) and BHF177 (3.75-30 mg/kg, i.p.) were used to see the effects on 9% alcoholic beer and near-beer self-administration. RESULTS: Near-beer stably maintained operant oral self-administration in mice. Adding ethanol to near-beer reduced the number of active lever presses, while the corresponding amount of ethanol self-administration increased (0.8-1.0 g/kg/session). Motor impairment was observed when more than 1.3 g/kg/session of ethanol was self-administered with beer and slight but consistent hyperlocomotion with more than 0.9-1.0 g/kg/session. BHF177 (15 mg/kg) preferentially reduced 9% alcoholic beer self-administration, while the higher dose (30 mg/kg)-like baclofen 5 mg/kg-also reduced near-beer self-administration. CONCLUSIONS: The operant model of oral alcoholic beer self-administration in C57BL/6J mice should prove useful for studying ethanol-reinforced behaviors and to identify candidate compounds for the pharmacological management of alcohol addiction.
Subject(s)
Beer , Conditioning, Operant/drug effects , Ethanol/pharmacology , GABA-B Receptor Agonists/pharmacology , Norbornanes/pharmacology , Pyrimidines/pharmacology , Allosteric Regulation/drug effects , Animals , Baclofen/pharmacology , Dose-Response Relationship, Drug , Ethanol/administration & dosage , Male , Maze Learning/drug effects , Mice , Mice, Inbred C57BL , Models, Animal , Motor Activity/drug effects , Reinforcement Schedule , Rotarod Performance Test/methods , Self Administration/methodsABSTRACT
Environmental stimuli repeatedly associated with the self-administered drugs may acquire motivational importance. Because dopamine (DA) D(2) /D(3) partial agonists and D(3) antagonists interfere with the ability of drug-associated cues to induce drug-seeking behaviour, the present study investigated whether bifeprunox, 7-[4-([1,1'biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone mesylate), a high-affinity partial agonist of the D(2) subfamily of DA receptors and of serotonin(1A) receptors, influences reinstatement of drug-associated cue-induced nicotine-seeking behaviour. The study also explored whether bifeprunox reduced motivated behaviour by evaluating its effects on reinstatement induced by stimuli conditioned to sucrose. To verify whether bifeprunox interferes with the primary reinforcing properties of either drug or sucrose, we compared its effects on nicotine self-administration and on sucrose-reinforced behaviour. Different groups of experimentally naïve, food-restricted Wistar rats were trained to associate a discriminative stimulus with response-contingent availability of nicotine or sucrose and tested for reinstatement after extinction of nicotine or sucrose-reinforced behaviour. Bifeprunox (4-16 µg/kg, s.c.) dose-dependently attenuated the response-reinstating effects of nicotine-associated cues. Higher doses (64-250 µg/kg, s.c.) reduced spontaneous locomotor activity and suppressed operant responding induced by sucrose-associated cues and by the primary reinforcing properties of nicotine or sucrose. Provided they can be extrapolated to abstinent human addicts, these results suggest the potential therapeutic use of partial DA D(2) receptor agonist to prevent cue-controlled nicotine-seeking and relapse. The profile of action of high doses of bifeprunox remains to be examined for potential sedation or anhedonia effects.
Subject(s)
Benzoxazoles/pharmacology , Dopamine D2 Receptor Antagonists , Drug-Seeking Behavior/drug effects , Piperazines/pharmacology , Serotonin 5-HT1 Receptor Antagonists/pharmacology , Tobacco Use Disorder/drug therapy , Tobacco Use Disorder/economics , Analysis of Variance , Animals , Conditioning, Operant/drug effects , Cues , Eating/drug effects , Feeding Behavior/drug effects , Male , Motor Activity/drug effects , Nicotine/administration & dosage , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT1A/drug effects , Recurrence , Reinforcement, Psychology , Self Administration , Sucrose/administration & dosageABSTRACT
Gamma-hydroxybutyric acid (GHB) is an endogenous brain substance that has diverse neuropharmacological actions, including rewarding properties in different animal species and in humans. As other drugs of abuse, GHB affects the firing of ventral tegmental neurons (VTA) in anaesthetized animals and hyperpolarizes dopaminergic neurons in VTA slices. However, no direct behavioural data on the effects of GHB applied in the VTA or in the target regions of its dopaminergic neurons, e.g. the nucleus accumbens (NAc), are available. Here, we investigated the effects of various doses of intravenous GHB in maintaining self-administration (from 0.001 to 10 mg/kg per infusion), and its ability to induce conditioned place preference (CPP) in rats when given orally (175-350 mg/kg) or injected directly either in the VTA or NAc (from 10 to 300 microg/0.5 microl per side). Our results indicate that while only 0.01 mg/kg per infusion GHB maintained self-administration, although not on every test day, 350 mg/kg GHB given orally induced CPP. CPP was also observed when GHB was injected in the VTA (30-100 microg/0.5 microl per side) but not in the NAc. Together with recent in-vitro findings, these results suggest that the rewarding properties of GHB mainly occur via disinhibition of VTA dopaminergic neurons.